GBX1 Activators
GBX1 activators encompass a suite of chemical compounds that orchestrate an indirect enhancement of GBX1's functional activity by modulating various cellular signaling pathways. Compounds such as Forskolin and IBMX elevate intracellular cAMP levels, thereby activating PKA, which may result in the phosphorylation of GBX1 or its interacting partners, indirectly augmenting GBX1's role in cellular signaling. Similarly, Rolipram acts as a selective PDE4 inhibitor, leading to increased cAMP levels and potentially enhancing PKA activity that could favor GBX1 activity. The cAMP analog 8-Br-cAMP directly stimulates PKA, which can also lead to an enhanced functional state of GBX1. PMA, a potent activator of PKC, and Epigallocatechin gallate (EGCG), a kinase inhibitor, could modify various signaling cascades, potentially culminating in the upregulation of GBX1 activity.
The PI3K inhibitor LY294002 may indirectly increase GBX1 activity by influencing downstream signaling processes, and similarly, the MEK inhibitors PD98059 and U0126 can lead to alterations in the MAPK/ERK pathway, which may indirectly benefit the functional status of GBX1. SP600125, a JNK inhibitor, could also create favorable conditions for GBX1 activation by modifying JNK pathway signaling. Sildenafil, known for inhibiting PDE5 and preventing cAMP and cGMP breakdown, supports enhanced signaling pathways that could upregulate GBX1 activity, such as those mediated by PKG or PKA. Collectively, these activators work through distinct yet interconnected pathways to promote the cellular activity of GBX1 without directly increasing its expression or serving as direct ligands.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylyl cyclase, increasing intracellular cAMP levels. Elevated cAMP activates PKA, which can phosphorylate GBX1 or its partners, enhancing GBX1's activity in cellular processes. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
IBMX is a non-selective inhibitor of phosphodiesterases, which prevents cAMP degradation, leading to enhanced PKA activity that could indirectly increase GBX1 activity through phosphorylation. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632 is a ROCK inhibitor that leads to decreased phosphorylation of downstream targets, potentially reducing inhibitory control over GBX1, thereby indirectly enhancing its activity. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) activates protein kinase C (PKC), which can modulate signaling pathways that may upregulate GBX1 activity as part of cellular responses to increased PKC activity. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Rolipram is a selective inhibitor of phosphodiesterase 4 (PDE4), leading to an increase in cAMP levels which may enhance PKA activity and subsequently, GBX1's role in cellular signaling. | ||||||
8-Bromoadenosine 3′,5′-cyclic monophosphate | 23583-48-4 | sc-217493B sc-217493 sc-217493A sc-217493C sc-217493D | 25 mg 50 mg 100 mg 250 mg 500 mg | $108.00 $169.00 $295.00 $561.00 $835.00 | 2 | |
8-Bromoadenosine 3',5'-cyclic monophosphate (8-Br-cAMP) is a cAMP analog that activates PKA, which may enhance GBX1 activity through phosphorylation of GBX1 or associated regulatory proteins. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Epigallocatechin gallate (EGCG) inhibits multiple kinases, potentially altering signaling cascades that lead to the activation of GBX1 by shifting the balance of phosphorylation within the cell. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor, which may lead to altered downstream signaling that can enhance GBX1's activity by affecting cellular processes that involve GBX1 indirectly. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor, which may influence MAPK/ERK pathway activity, leading to changes in signaling that could indirectly enhance GBX1 activity by modifying the phosphorylation status of proteins that interact with GBX1. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, which may indirectly enhance GBX1 activity by altering JNK pathway signaling and its downstream effects on cellular processes involving GBX1. | ||||||